Trial Profile
COVID-19: A Phase 1, Partially Blind, Placebo-controlled, Dose Escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2023
Price :
$35
*
At a glance
- Drugs Zorecimeran (Primary)
- Indications COVID-19 respiratory infection
- Focus Adverse reactions; First in man
- Sponsors CureVac
- 22 Dec 2021 Status changed from active, no longer recruiting to completed.
- 26 Oct 2021 Planned End Date changed from 1 Dec 2021 to 1 Jan 2022.
- 26 Oct 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Jan 2022.